Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory Council
September 03 2019 - 4:05PM
Business Wire
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today
announced that the U.S. Department of Commerce has selected Brendan
O’Grady, Executive Vice President and Head of North America
Commercial to serve on the U.S. Investment Advisory Council. The
Council is a 25-member panel of national experts who will counsel
and advise Secretary of Commerce Wilbur Ross on attracting and
retaining foreign direct investment in the U.S.
O’Grady’s appointment reflects recognition of his deep expertise
spanning more than 28 years in the pharmaceutical industry.
“I am honored to be selected to serve on the Council and provide
a unique perspective on the impact and value of foreign direct
investment on the pharmaceutical industry in the U.S.,” says
O’Grady. “This is especially important as foreign investments can
affect domestic innovation for new therapies and help ensure a
strong supply chain for safe, effective and lower cost generic
therapies.”
Chartered in 2016, the U.S. Investment Advisory Council makes
recommendations on infrastructure investment priorities, workforce
development initiatives, and groundbreaking strategies to support
economic development through new digital tools. Collectively, those
recommendations are mobilized to generate additional foreign direct
investment in the U.S.
O’Grady is also a current member of the board of directors and
the compensation committee chair for American Well, a leading U.S.
based telemedicine company, and is a Board Member of the
Association for Accessible Medicines which represents the generic
and biosimilar industries in the U.S.
About Teva
Established in Israel in 1901, Teva Pharmaceutical Industries
Ltd. (NYSE and TASE: TEVA) has been developing and producing
medicines to improve people’s lives for more than a century. We are
a global leader in generic and specialty medicines with a portfolio
consisting of over 3,500 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine
every day, and are served by one of the largest and most complex
supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of
specialty and biopharmaceutical products. Learn more at
www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to our ability to successfully
compete in the marketplace; our substantial indebtedness, which may
limit our ability to incur additional indebtedness, engage in
additional transactions or make new investments; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Quarterly Reports on Form
10-Q for the first and second quarter of 2019 and in our Annual
Report on Form 10-K for the year ended December 31, 2018, including
in the sections captioned "Risk Factors” and “Forward Looking
Statements.” Forward-looking statements speak only as of the date
on which they are made, and we assume no obligation to update or
revise any forward-looking statements or other information
contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005739/en/
IR Contacts United States Kevin C. Mannix (215) 591-8912
Ran Meir 972 (3) 926-7516
PR Contacts United States Kelley Dougherty (973)
658-0237 Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2024 to May 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From May 2023 to May 2024